About Gate2Brain
Gate2Brain is a company based in Barcelona (Spain) founded in 2019 by Esther Riambau, Gloria Sanclimens Perez De Rozas, and Marc Ramis Castelltort. Gate2Brain has raised $8.12 million across 3 funding rounds from investors including European Union, EIC Fund and Shilpa Medicare. Gate2Brain offers products and services including G2B-002 and Peptide Shuttles Platform. Gate2Brain operates in a competitive market with competitors including Ironwood Pharma, VeraDermics, Lipum, Proveca and Castle Creek Biosciences, among others.
- Headquarter Barcelona, Spain
- Founders Esther Riambau, Gloria Sanclimens Perez De Rozas, Marc Ramis Castelltort
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gate2brain S.L.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.12 M (USD)
in 3 rounds
-
Latest Funding Round
$8.12 M (USD), Series A
Jun 17, 2026
-
Investors
European Union
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gate2Brain
Gate2Brain offers a comprehensive portfolio of products and services, including G2B-002 and Peptide Shuttles Platform.
Drug for treating rare pediatric cancers by enhancing delivery across barriers
System for improving biopharmaceutical properties of various drug cargoes
People of Gate2Brain
Unlock access to complete
Unlock access to complete
Funding Insights of Gate2Brain
Gate2Brain has successfully raised a total of $8.12M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $8.12 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gate2Brain
Gate2Brain has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EIC Fund and Shilpa Medicare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Gate2Brain
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gate2Brain
Investment portfolio details for Gate2Brain
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gate2Brain
Detailed financials for Gate2Brain
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gate2brain Comparisons
Peer comparison for Gate2Brain
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gate2Brain
Gate2Brain operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, VeraDermics, Lipum, Proveca and Castle Creek Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Drug-delivery platforms for pediatric wart treatments are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody to treat juvenile idiopathic arthritis
|
|
| Locked | Locked | Locked |
Medicines for chronic diseases in children are developed and provided.
|
|
| Locked | Locked | Locked |
Gene therapy platform for rare disease treatments is developed.
|
|
| Locked | Locked | Locked |
Therapies for pediatric neurology, oncology, and hematology are developed.
|
Detailed competitors of Gate2Brain
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gate2brain
Complete news archive for Gate2Brain
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gate2Brain
Gate2Brain was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Gate2Brain is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Gate2Brain is a funded company, having raised a total of $8.12M across 3 funding rounds to date.
A platform for delivering therapeutics across biological barriers, including the blood-brain barrier, is developed using patented peptide-based technology. The company was founded in 2019 and is based in Barcelona, Spain, within the biotechnology sector. Operations focus on creating treatments for central nervous system conditions, with the flagship product G2B-002 targeted at pediatric CNS tumors.
Gate2Brain's top competitors include Ironwood Pharma, Castle Creek Biosciences and VeraDermics.
Gate2Brain offers G2B-002 and Peptide Shuttles Platform.
Gate2Brain has 3 investors. Key investors include European Union, EIC Fund, and Shilpa Medicare.